NantKwest

89 articles about NantKwest

• NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit

  3/18/2019

  NantKwest, a leading clinical-stage, natural killer cell based therapeutics company, announced that the company’s Chairman & CEO, Dr. Patrick Soon-Shiong, will be giving a keynote address at the Innate Killer Summit in San Diego on Wednesday, March 20, 2019.

• NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics

  3/4/2019

  Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate for Multiple Myeloma, with an Option for up to Five Additional CAR Targeting Sequences

• 

  Where Are They Now? Top 3 Biotech Startups From NextGen Bio 2016

  2/6/2019

  Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.

• NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs

  1/5/2019

  NantKwest today announced that the company will be hosting an Investor/Analyst Day on Tuesday, January 8, 2019 in San Francisco, California.

• NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference

  11/6/2018

  Update on Off-The-Shelf CD16 Targeted NK Cell (haNK) and NANT Cancer Vaccine Program Including Interim Data Analysis for Pancreatic Cancer, Triple Negative Breast Cancer & Head and Neck Cancer Trials

• NantKwest to Present at 2018 Cantor Global Healthcare Conference

  10/2/2018

  NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2nd in New York City During the conference, company management will be presenting a corporate overview, as well as conducting one-on-one meetings to provide a corporate update, as well as review R&D and clinical activities.

• 

  Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

  6/20/2018

  The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.

• NantKwest Names Sonja Nelson Chief Financial Officer

  6/19/2018

  NantKwest, Inc. announced the elevation of Sonja Nelson, chief accounting officer for the company, to the role of Chief Financial Officer (CFO).

• NantKwest to Present at Jefferies 2018 Global Healthcare Conference

  6/5/2018

  NantKwest announced that Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest, will be presenting and conducting one-on-one meetings at the upcoming Jefferies Global Healthcare Conference

• NantKwest to Present at Upcoming Investment and Healthcare Conferences

  3/13/2018

  NantKwest announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the month of March and April 2018.

• Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma

  2/13/2018

  The study is being led by Dr. Michael Burger, principal investigator, together with co-principal investigators Professor Joachim Steinbach, Head of the Institute for Neuro-oncology at the Goethe University Hospital, and Professor Christian Senft, Department of Neurosurgery at the Goethe University Hospital in Frankfurt/Main, Germany.

• NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine

  1/5/2018

  NantKwest announced today that the company will be hosting an Investor/Analyst Day on Tuesday, January 9th in San Francisco, California.

• NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology

  12/4/2017

  This oral presentation will present preclinical data on the company’s CD19.taNK program.

• NantKwest Announces Successful First In Human Administration Of CD16 High Affinity Natural Killer (haNK) Cells

  10/2/2017

• NantKwest Builds Financial And Commercial Expertise With The Appointment Of Fred Driscoll To Its Board Of Directors

  9/25/2017

• NantKwest To Present At The 37th Annual Canaccord Genuity Growth Conference

  8/7/2017

• NantKwest Announces Durable Complete Responses In Ph1 Trial Of Ank Cell Therapy In Patients With Relapsed Hematological Malignancies

  8/1/2017

• NantKwest Announces Publication Of Preclinical Data Of Hank Cell Therapy In Combination With Checkpoint Inhibitor Avelumab Providing Strong Rationale For Advancement To Human Clinical Trials

  7/25/2017

• NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages Of Disease

  6/6/2017

• Controversial NantKwest CEO Appointed To National Health IT Advisory Committee

  6/1/2017